Cytokinetics Stock News

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) have been assigned an average rating of Buy from the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among brokers that []

Comerica Bank lessened its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,910 shares of the biopharmaceutical companys stock after selling 4,720 shares during the period. Comerica Bank owned approximately 0.08% []

AQR Capital Management LLC lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 35.8% during the second quarter, Holdings Channel.com reports. The firm owned 10,135 shares of the biopharmaceutical companys stock after selling 5,642 shares during the period. AQR Capital Management LLCs holdings in Cytokinetics were worth $201,000 at the end of the most recent quarter. []

Analysts expect Cytokinetics, Incorporated (NASDAQ:CYTK) to post $6.00 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Cytokinetics earnings. The highest sales estimate is $8.57 million and the lowest is $440,000.00. Cytokinetics posted sales of $6.72 million during the same quarter last year, which suggests a []

Here are the five best biotech ETFs to invest in right now.

Prudential Financial Inc. cut its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,198 shares of the biopharmaceutical companys stock after selling 3,617 shares during the quarter. Prudential Financial Inc. owned about 0.09% of Cytokinetics worth []

Wall Street brokerages expect Cytokinetics, Incorporated (NASDAQ:CYTK) to post ($0.82) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have issued estimates for Cytokinetics earnings, with the lowest EPS estimate coming in at ($0.93) and the highest estimate coming in at ($0.66). Cytokinetics posted earnings per share of ($0.62) in the same []

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sandford D. Smith sold 29,032 shares of the businesss stock in a transaction dated Friday, November 19th. The stock was sold at an average price of $41.21, for a total transaction of $1,196,408.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this []

Credit Suisse AG lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 19.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 97,567 shares of the biopharmaceutical companys stock after selling 24,041 shares during the quarter. Credit Suisse AG owned about 0.12% of Cytokinetics worth $1,931,000 []

Nuveen Asset Management LLC reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 13.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 257,432 shares of the biopharmaceutical companys stock after selling 38,434 shares during the period. Nuveen Asset Management LLC owned approximately 0.31% of Cytokinetics worth []

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual Healthcare Conference taking place November 30, 2021 to December 2, 2021.

Related Stocks: EPZM , MRUS , ADCT , YMAB , MEIP , NTLA , BCRX , CYTK , VSTM , GERN ,

Analysis from GALACTIC-HF Shows Treatment with Omecamtiv Mecarbil Associated with Significant Reduction in the Risk of Stroke

Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q3 2021 Results - Earnings Call Transcript

Cytokinetics (CYTK) delivered earnings and revenue surprises of -26.67% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?